ArticlemedRxiv : the preprint server for health sciences2025
VADEr: Vision Transformer-Inspired Framework for Polygenic Risk Reveals Underlying Genetic Heterogeneity in Prostate Cancer.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Polygenic risk scores (PRSs) serve as quantitative metrics of genetic liability for various conditions. Traditionally calculated as an effect size weighted genotype summation, this formulation assumes conditional feature independence and overlooks the potential for complex interactions among genetic variants. Transformers, a class of deep learning architectures known for capturing dependencies between features, have demonstrated remarkable predictive power across domains. In this work, we introduce VADEr, a Vision Transformer (ViT)-inspired architecture that combines techniques from both natural language processing and computer vision to capture properties exhibited by genetic data and model local and global interactions for genotype-to-phenotype prediction. Evaluating VADEr's performance in predicting prostate cancer (PCa) risk, we found that across a range of metrics, including accuracy, average precision, and Matthews correlation coefficient, VADEr outperformed all benchmark methods, demonstrating its effectiveness in the context of complex disease risk prediction. To illuminate identified drivers of disease risk by VADEr, we formulated DARTH scores, an attention-based attribution metric, to capture the personalized contribution of each genomic region. These scores revealed distinct genetic heterogeneity captured by VADEr, with drivers of predicted risk identified in key PCa risk regions including the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.